spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Saudi Arabia E-Pharmacy Forecast & Opportunities Report 2025: A $2.1 Billion Market by 2030

The Saudi Arabia E-Pharmacy Market was valued at USD 923.56 Million in 2024 and is projected to reach USD 2.10 Billion by 2030, rising at a CAGR of 14.76%.

The market is witnessing robust growth due to increased internet and smartphone usage, making healthcare more accessible via digital platforms. Consumers are shifting towards online pharmacies for prescription and over-the-counter medications, drawn by convenience and product availability.

The rise in chronic diseases such as diabetes and hypertension further drives the need for reliable pharmaceutical access. Government initiatives promoting digital health, coupled with supportive e-commerce regulations, are enhancing sector growth. As awareness and digital engagement increase, the demand for e-pharmacy solutions is expanding rapidly across the Kingdom.

Growing Internet Penetration
Expanding internet usage is a key growth driver in Saudi Arabia’s e-pharmacy sector. As of early 2024, the country recorded a 99.0% internet penetration rate, with over 36.84 million users. This widespread connectivity enables consumers to access e-pharmacy platforms easily through smartphones, supporting on-the-go purchasing and prescription management.

The convenience of comparing prices, browsing a wide range of products, and receiving doorstep delivery has led more users to adopt online pharmacy services. The digital shift is further encouraged by the rise in e-commerce infrastructure and growing acceptance of telehealth solutions. As digital inclusion spreads across urban and rural regions, the e-pharmacy market is expected to experience sustained growth.

Hot this week

Novo Nordisk Lowers Full-Year Profit Guidance in New CEO’s Maiden Quarter

Wegovy-maker Novo Nordisk lowered its full-year profit forecast on...

Compass Pathways to expedite launch timing of its experimental depression therapy

Drug developer Compass Pathways said on Tuesday it is...

Pharma Investment to establish manufacturing facility at SOHAR Freezone

SOHAR Port and Freezone has signed a land lease...

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img